27496 Efficacy of ruxolitinib cream for the treatment of atopic dermatitis by baseline patient demographics: Pooled subgroup analysis from two randomized phase 3 studies

Abstract

Atopic dermatitis (AD) is a highly pruritic, chronic, inflammatory skin disease. Ruxolitinib cream is a Janus kinase (JAK) 1/JAK2 inhibitor in development for the treatment of AD. Two phase 3, randomized studies (TRuE-AD1 [NCT03745638]; TRuE-AD2 [NCT03745651]) enrolled patients aged ≥12 years with AD for ≥2 years, an Investigator’s Global Assessment (IGA) score of 2 or 3, and 3%–20% affected body surface area. Patients (total N = 1249; median age, 32 years) were randomized (2:2:1) to 0.75% ruxolitinib, 1.5% ruxolitinib, or vehicle cream (all twice daily) for 8 weeks of double-blind treatment.